Wire · opportunities
A Breakthrough Blood Test for Prostate Cancer To be Premiered by 5Q Spectra at Davos of ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
5Q Spectra is launching Prostate Dx™, a blood test that improves the diagnosis of clinically significant prostate cancer by distinguishing it from benign causes of elevated PSA, potentially reducing unnecessary biopsies by up to 44%. The test combines blood biomarkers with imaging and AI, achieving up to 95% sensitivity and an AUC of 0.92 when combined with other diagnostics.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now target urologists and oncologists with a validated test that cuts unnecessary prostate biopsies nearly in half. Medical device and diagnostic startups focused on cancer should explore integrating blood biomarkers with AI imaging to win this evolving clinical standard.
◆ Coverage
1 source · 8 Sep 2026
◆ Related on Wire
◆ Topics